3717 related articles for article (PubMed ID: 28427875)
1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
;
J Hepatol; 2017 Aug; 67(2):370-398. PubMed ID: 28427875
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
3. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò M; Mangia G; Lampertico P
Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
[TBL] [Abstract][Full Text] [Related]
4. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.
Yuen MF; Ahn SH; Chen DS; Chen PJ; Dusheiko GM; Hou JL; Maddrey WC; Mizokami M; Seto WK; Zoulim F; Lai CL
J Clin Gastroenterol; 2016 Apr; 50(4):286-94. PubMed ID: 26840752
[TBL] [Abstract][Full Text] [Related]
5. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
6. [Interdisciplinary aspects of and new drugs for chronic hepatitis B].
Horváth G
Orv Hetil; 2013 Jul; 154(29):1142-50. PubMed ID: 23853347
[TBL] [Abstract][Full Text] [Related]
7. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
Lampertico P; Viganò M; Colombo M
Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
[TBL] [Abstract][Full Text] [Related]
8. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
10. Taiwan consensus statement on the management of chronic hepatitis B.
Chien RN; Kao JH; Peng CY; Chen CH; Liu CJ; Huang YH; Hu TH; Yang HI; Lu SN; Ni YH; Chuang WL; Lee CM; Wu JC; Chen PJ; Liaw YF
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):7-38. PubMed ID: 30527436
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis B virus infection in Asian countries.
Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
[TBL] [Abstract][Full Text] [Related]
12. Management of chronic hepatitis B.
Wilt TJ; Shamliyan T; Shaukat A; Taylor BC; MacDonald R; Yuan JM; Johnson JR; Tacklind J; Rutks I; Kane RL
Evid Rep Technol Assess (Full Rep); 2008 Oct; (174):1-671. PubMed ID: 19408969
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B: Who and when to treat?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2018 Feb; 38 Suppl 1():71-78. PubMed ID: 29427495
[TBL] [Abstract][Full Text] [Related]
14. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus.
Broquetas T; Carrión JA
Hepat Med; 2022; 14():87-100. PubMed ID: 35936810
[TBL] [Abstract][Full Text] [Related]
15. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
16. Current view on hepatitis B diagnosis and therapy.
Husa P
Vnitr Lek; 2019; 65(9):546-551. PubMed ID: 31635465
[TBL] [Abstract][Full Text] [Related]
17. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Viganò M; Invernizzi F; Lampertico P
Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
[TBL] [Abstract][Full Text] [Related]
18. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
Dusheiko G
Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.
Seo Y; Yano Y
World J Gastroenterol; 2014 Oct; 20(37):13284-92. PubMed ID: 25309065
[TBL] [Abstract][Full Text] [Related]
20. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
